HELP (Helus Pharma Inc.) stock: $8.96, $654.6M market cap, $94.0M cash, $560.6M EV, $462.6M fully diluted market cap. Lead program: CYB003 (Major Depressive Disorder), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective therapeutics for patients who suffer with a range of mental health conditions, advancing psychedelic-based therapeutics including its deuterated psilocybin analog CYB003 in clinical development for major depressive disorder.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.